Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
Primary Purpose
Erectile Dysfunction, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
HUC-MSCs
Injectable Collagen Scaffold + HUC-MSCs
Sponsored by
About this trial
This is an interventional treatment trial for Erectile Dysfunction
Eligibility Criteria
Inclusion Criteria:
- Type 1 or 2 diabetes,blood glucose controlled well, no effective with oral PDE-5i
- Have a consistent partner who is willing to engage in sexual activity more than twice per month during the study
- Males, age 20-65 years
- IIEF-5 score is under 16
- Penile arterial insufficiency or venous leakage (doppler): peak systolic velocity(PSV) <25 cm/sec, or peak systolic velocity(PSV)>25 cm/sec, end-diastolic velocity(EDV)> 5cm/sec, resistance index(RI)<0.75
- HbA1c is between 6.5%-10%
- Physical examination with no abnormalities
- Willing to consent to participate in the study follow-up
- Willing to limit alcohol intake eliminate use of recreational drugs for sexual encounters.
Exclusion Criteria:
- Severe cardiovascular disease (angina, arrhythmia, cardiac failure, stroke), kidney failure, respiratory failure; history of malignancy
- Positive for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) syphilis test
- Testosterone level is less than 200ng/dL
- Serum AST/ALT >3*upper limit of normal or creatinine >1.5*upper limit of normal
- HbA1c exhibit greater than 10%
- In the investigators judgment, with clinical significance of penis abnormalities, or has received penile prosthesis implantation surgery
- Patients partner is trying to conceive during the trial period
- Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study
- Unwilling and/or not able to give written informed consent
Sites / Locations
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
HUC-MSCs
Injectable Collagen Scaffold + HUC-MSCs
Arm Description
Intracavernous injection of 15 million HUC-MSCs.
Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs.
Outcomes
Primary Outcome Measures
Safety and Tolerability assessed by Adverse Events
Secondary Outcome Measures
Improvement in IIEF-5 (International Index of Erectile Function)
The subjects must fill in the questionnaire of IIEF-5 every visit to evaluate erectile function
Improvement in penile colour Doppler ultrasonography
Full Information
NCT ID
NCT02745808
First Posted
April 12, 2016
Last Updated
January 23, 2019
Sponsor
Chinese Academy of Sciences
Collaborators
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
1. Study Identification
Unique Protocol Identification Number
NCT02745808
Brief Title
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
Official Title
Injectable Collagen Scaffold™ Combined With Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) for the Improvement of Erectile Function in Men With Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
April 2016
Overall Recruitment Status
Unknown status
Study Start Date
September 2015 (undefined)
Primary Completion Date
December 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese Academy of Sciences
Collaborators
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The intent of this clinical study is to answer the questions: 1) is the proposed treatment feasible; 2) is treatment effective in improving the disease pathology of patients with diagnosed diabetic erectile dysfunction.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erectile Dysfunction, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
HUC-MSCs
Arm Type
Experimental
Arm Description
Intracavernous injection of 15 million HUC-MSCs.
Arm Title
Injectable Collagen Scaffold + HUC-MSCs
Arm Type
Experimental
Arm Description
Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs.
Intervention Type
Biological
Intervention Name(s)
HUC-MSCs
Intervention Description
The subjects will receive intracavernous injection of HUCMSC.
Intervention Type
Biological
Intervention Name(s)
Injectable Collagen Scaffold + HUC-MSCs
Intervention Description
The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
Primary Outcome Measure Information:
Title
Safety and Tolerability assessed by Adverse Events
Time Frame
1 month after intervention
Secondary Outcome Measure Information:
Title
Improvement in IIEF-5 (International Index of Erectile Function)
Description
The subjects must fill in the questionnaire of IIEF-5 every visit to evaluate erectile function
Time Frame
1,3,6,9 and 12 months
Title
Improvement in penile colour Doppler ultrasonography
Time Frame
1,3,6,9 and 12 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 1 or 2 diabetes,blood glucose controlled well, no effective with oral PDE-5i
Have a consistent partner who is willing to engage in sexual activity more than twice per month during the study
Males, age 20-65 years
IIEF-5 score is under 16
Penile arterial insufficiency or venous leakage (doppler): peak systolic velocity(PSV) <25 cm/sec, or peak systolic velocity(PSV)>25 cm/sec, end-diastolic velocity(EDV)> 5cm/sec, resistance index(RI)<0.75
HbA1c is between 6.5%-10%
Physical examination with no abnormalities
Willing to consent to participate in the study follow-up
Willing to limit alcohol intake eliminate use of recreational drugs for sexual encounters.
Exclusion Criteria:
Severe cardiovascular disease (angina, arrhythmia, cardiac failure, stroke), kidney failure, respiratory failure; history of malignancy
Positive for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) syphilis test
Testosterone level is less than 200ng/dL
Serum AST/ALT >3*upper limit of normal or creatinine >1.5*upper limit of normal
HbA1c exhibit greater than 10%
In the investigators judgment, with clinical significance of penis abnormalities, or has received penile prosthesis implantation surgery
Patients partner is trying to conceive during the trial period
Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study
Unwilling and/or not able to give written informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhifeng Xiao, Ph.D
Phone
86-10-82614420
Email
zfxiao@genetics.ac.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Sufang Han, Ph.D
Phone
86-10-82614420
Email
sufanghan22@genetics.ac.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jianwu Dai, Ph.D
Organizational Affiliation
Chinese Academy of Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yutian Dai, M.D.
Phone
86-25-83106666
Ext
70502
Email
13913957628@163.com
First Name & Middle Initial & Last Name & Degree
LeiLei Zhu, M.D.
Phone
86-25-83106666
Ext
70502
Email
zhuleilei68n@163.com
12. IPD Sharing Statement
Learn more about this trial
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
We'll reach out to this number within 24 hrs